Bortezomib-Based Regimens and Plasma Cell Leukemia

Kaynakça

1. Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, Gay F, Hegenbart U, Hajek R, Zweegman S, Bruno B, Straka C, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M, Terpos E. European Myeloma Network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia 2018;32:1883-1898.

2. Wang H, Zhou H, Zhang Z, Geng C, Chen W. Bortezomib-based regimens improve the outcome of patients with primary or secondary plasma cell leukemia: a retrospective cohort study. Turk J Hematol 2020;37:91-97.

3. Lawless S, Iacobelli S, Knelange N, Chevallier P, Blaise D, Milpied NJ, Foà R, Cornelissen JJ, Lioure B, Potter V, Poire X, Petersen EJ, Collin MP, Lenhoff S, Snowden J, Santarone S, Wilson K, Guimaraes JE, Dreger P, Schipperus MR, Morris C, Schönland S, Yakoub-Agha I, Garderet L, Nicolaus K. Results of autologous and allogeneic transplantation in patients with primary plasma cell leukemia: a large retrospective analysis of the Chronic Malignancies Working Party of the EBMT. Blood 2018;132(Suppl 1):3425 (abstract).

4. Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant 2019;54:1089-1910.

5. Nolghranyan S, Singh AP, Schinke C. The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia. Am J Hematol 2020;95:E34-E35.

6. Horisawa Y, Kondo T, Hishizawa M, Yamashita K, Takaori-Kondo A. A case of allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia after treatment with daratumumab. Ann Hematol 2020;99:2699-2701.

Kaynak Göster

Turkish Journal of Hematology
  • ISSN: 1300-7777
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1999

310

Sayıdaki Diğer Makaleler

Original Versus Generic Lenalidomide in Patients with Relapsed/ Refractory Multiple Myeloma: Comparison of Efficacy and Adverse Events

Zahit BOLAMAN, Atakan TURGUTKAYA, Birsen SAHİP, Cem SELİM, Hilal EROĞLU KÜÇÜKDİLER, Şehmus ERTOP, Gökhan SARGIN, İrfan YAVAŞOĞLU

A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia

Wanlu MA, Jiawei ZHAO, Lu ZHANG

Peripheral Blood Smears in COVID-19: A Comment

Rujittika MUNGMUNPUNTİPANTİP, Viroj WIWANITKIT

Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia

Keisuke KİDOGUCHİ, Yasushi KUBOTA, Yuki NİSHİMURA, Haruna KİZUKA SANO, Shinya KİMURA

COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single-Center Survey from Turkey

Umut YILMAZ, Aslıhan PEKMEZCİ, Yalçın GÜL, Ahmet Emre EŞKAZAN

Bortezomib-Based Regimens and Plasma Cell Leukemia

Zahit BOLAMAN

Primary Immune Regulatory Disorders and Targeted Therapies

Burcu KOLUKISA, Safa BARIŞ

Current Practice in FFP Preparation and Use in Greece: A National Survey

Aspasia ARGYROU, serena VALSAMİ, Abraham POULİAKİS, Maria GAVALAKİ, Antonis AGGELİDS, Vasiliki VOULGARİDOU, Vasiliki PLİATSİKA, Theofanis ADRAKTAS, Andreas PAPACHRONİS, Chrysoula ALEPİ, Vasiliki GİANNOPOULOU, Panagiotis SİOUROUNİS, Sofia TSAGİA, Georges MARTİNİS, Eftihia KONTEKAKİ, Eleftheria ZERVOU, Spiridon KOLİO

Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation

Rafiye ÇİFTÇİLER, Hakan GÖKER, Haluk DEMİROĞLU, İbrahim Celalettin HAZNEDAROĞLU, Nilgün SAYINALP, Salih AKSU, Osman ÖZCEBE, Yahya BÜYÜKAŞIK

Hydroxychloroquine, TTP, COVID-19, and SLE

Pathum SOOKAROMDEE, Viroj WİWANİTKİT